tremelimumab,durvalumab,Sorafenib
AstraZeneca,Pfizer
['hcc', 'durva']
 asco-hcc patients who experienced irae on durva-treme achieved longer survival but! patients who survive longer are also more likely to experience irae curves are clear, but we need time-adjusted survival analysis #asco23 
Medical Oncologist and PhD student at Imperial College London.
HCC, immuno-oncology.
Curiosity-driven.